Lv3
234 积分 2024-01-08 加入
In vivo engineering of CAR immune cells by nonviral nanoparticles
3天前
已完结
Towards mRNA therapeutics 2.0
3天前
已完结
mRNA therapeutics: Molecular mechanisms, delivery platforms, regulatory frameworks, and equitable global access
3天前
已完结
Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR-T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer
6天前
已完结
Antibody-drug conjugates in colorectal cancer: advances, challenges, and prospectives
8天前
已完结
T-cell engagers in small-cell lung cancer: current evidence and future directions – a position statement from the ETOP IBCSG Partners Foundation Workshop
10天前
已完结
Glypican-3-targeted therapy in hepatocellular carcinoma: biological insights and therapeutic strategies
23天前
已完结
HER2-targeted therapies beyond breast cancer — an update
1个月前
已完结
Multispecific T-cell engagers attract cancer drug developers
1个月前
已完结
Trends in the landscape of clinical trials of innovative drugs in China since 2015
2个月前
已完结
皖公网安备34019202002308
